

Appendix 4E

Full Year Report

30 June 2018

CannPal Animal Therapeutics Limited

ABN 88 612 791 518

Results for announcement to the market

		June 2018	June 2017
Financial Results	Movement	\$	\$
Revenue from ordinary activities	1,101%	76,799	6,392
Loss from ordinary activities after tax attributable to members	0.37%	1,694,369	1,688,197
Net loss for the period attributable to members	0.37%	1,694,369	1,688,197

Dividends	Amount per Ordinary Security
2018 final dividend	N/A
2017 final dividend	N/A

Net Tangible Asset Backing	June 2018	June 2017
Net tangible asset backing per ordinary security	\$0.05	\$0.01

Earnings Per Share (Basic and Diluted)	June 2018	June 2017
Earnings per share attributable to the ordinary equity - cents	(2.02)	(7.11)

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2018**

	30 June 2018 \$	30 June 2017 \$
Income		
Research & Development tax refund	129,113	-
Interest income	<u>76,799</u>	<u>6,392</u>
Total income	<u>205,912</u>	<u>6,392</u>
Expenses		
Employee expenses	110,240	70,296
Legal and ASX fees	232,347	62,695
Research & Development	661,317	334,649
Corporate and Administration costs	570,623	310,760
Share based payments	<u>325,754</u>	<u>916,189</u>
Total expenses	<u>(1,900,281)</u>	<u>(1,694,589)</u>
Loss before income tax	(1,694,369)	(1,688,197)
Income tax benefit/(expense)	<u>-</u>	<u>-</u>
Loss after income tax	<u>(1,694,369)</u>	<u>(1,688,197)</u>
Net loss for the year attributable to members of CannPal Animal Therapeutics Limited	<u>(1,694,369)</u>	<u>(1,688,197)</u>
Other comprehensive income, net of tax	<u>-</u>	<u>-</u>
Total comprehensive loss for the year attributable to the members of CannPal Animal Therapeutics Limited	<u>(1,694,369)</u>	<u>(1,688,197)</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
BALANCE SHEET
AS AT 30 JUNE 2018**

	30 June 2018 \$	30 June 2017 \$
ASSETS		
Current assets		
Cash and cash equivalents	5,114,239	754,188
Trade and other receivables	<u>26,644</u>	<u>25,579</u>
Total current assets	<u>5,140,883</u>	<u>779,767</u>
Total assets	<u>5,140,883</u>	<u>779,767</u>
LIABILITIES		
Current liabilities		
Trade and other payables	102,693	37,823
Provisions	<u>28,701</u>	<u>3,840</u>
Total current liabilities	<u>131,394</u>	<u>41,663</u>
Total liabilities	<u>131,394</u>	<u>41,663</u>
Net assets	<u>5,009,489</u>	<u>738,104</u>
EQUITY		
Issued capital	6,975,607	1,510,112
Reserves	1,416,448	916,189
Accumulated losses	<u>(3,382,566)</u>	<u>(1,688,197)</u>
Total equity	<u>5,009,489</u>	<u>738,104</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF CASH FLOW
FOR THE YEAR ENDED 30 JUNE 2018**

	30 June 2018 \$	30 June 2017 \$
Cash flows from operating activities		
Payments to suppliers and employees	(1,485,861)	(762,316)
Research & Development tax refund	129,113	-
Interest received	<u>76,799</u>	<u>6,392</u>
Net cash outflows from operating activities	<u>(1,279,949)</u>	<u>(755,924)</u>
Cash flows from financing activities		
Proceeds from the issue of shares	6,000,000	1,510,112
Share issue costs	<u>(360,000)</u>	<u>-</u>
Net cash inflows from financing activities	<u>5,640,000</u>	<u>1,510,112</u>
Net increase in cash and cash equivalents	4,360,051	754,188
Cash and cash equivalents at the beginning of the financial year	<u>754,188</u>	<u>-</u>
Cash and cash equivalents at end of year	<u>5,114,239</u>	<u>754,188</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2018**

	Issued capital \$	Share based payments reserve \$	Accumulated losses \$	Total \$
Balance at 1 July 2017	1,510,112	916,189	(1,688,197)	738,104
Total Comprehensive Income				
Loss for the year	-	-	(1,694,369)	(1,694,369)
Total comprehensive loss for the year	-	-	(1,694,369)	(1,694,369)
<i>Transactions with owners in their capacity as owners</i>				
Share based payment	-	500,259	-	500,259
Share issues	6,000,000	-	-	6,000,000
Share issue costs	(534,505)	-	-	(534,505)
Balance at 30 June 2018	6,975,607	1,416,448	(3,382,566)	5,009,489
Balance at 1 July 2016	-	-	-	-
Total Comprehensive Income				
Loss for the year	-	-	(1,688,197)	(1,688,197)
Total comprehensive loss for the year	-	-	(1,688,197)	(1,688,197)
<i>Transactions with owners in their capacity as owners</i>				
Share based payment	-	916,189	-	916,189
Share issues	1,510,112	-	-	1,510,112
Balance at 30 June 2017	1,510,112	916,189	(1,688,197)	738,104

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
FOR THE YEAR ENDED 30 JUNE 2018**

	30 June 2018 Number	30 June 2017 Number
EARNINGS PER SHARE		
Weighted average number of ordinary shares outstanding during the year used in the calculation of basic earnings per share	<u>83,972,603</u>	<u>23,754,340</u>

ISSUED CAPITAL

	30 June 2018 Shares	30 June 2018 \$	30 June 2017 Shares	30 June 2017 \$
Ordinary shares fully paid	<u>93,125,000</u>	<u>6,975,607</u>	<u>62,500,000</u>	<u>1,510,112</u>

Movements in ordinary share capital:

Date	Details	Number of shares	\$
1 July 2017	Opening balance	62,500,000	1,510,112
16 October	Share issue @ 20 cents per share	30,000,000	6,000,000
	Share issue costs - cash	-	(360,000)
	Share issue costs – options non cash	-	(174,505)
8 December	Shares issued on conversion of performance rights	<u>625,000</u>	<u>-</u>
30 June 2018	Balance	<u>93,125,000</u>	<u>6,975,607</u>

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

CONTINGENT ASSETS & LIABILITIES

There are no contingent liabilities or contingent assets as at 30 June 2018.

EVENTS AFTER BALANCE SHEET DATE

The directors are not aware of any matter or circumstance that has significantly or may significantly affect the operations of the company or the results of those operations, or the state of affairs of the company in subsequent financial years.

Annual meeting

The annual meeting will be held as follows:

Place	BDO Offices, Sydney
Date	20 November 2018
Time	To be advised
Approximate date the annual report will be available	28 September 2018

Compliance Statement

- 1 This report has been prepared in accordance with AASB Standards, other AASB authoritative pronouncements and Urgent Issues Group Consensus Views or other standards acceptable to ASX.

Identify other standards used

- 2 This report, and the accounts upon which the report is based, use the same accounting policies.
- 3 This report does give a true and fair view of the matters disclosed.
- 4 This report is based on accounts which are in the process of being audited.
- 5 The entity has a formally constituted audit committee.

Date: 31 August 2018

Baden M Bowen
Company Secretary